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SUMMARY
The	 in vitro and	 in vivo activity	of	 diminazene	 (Dim),	 artesunate	 (Art)	 and	 combination	of	Dim	and	Art	 (Dim‑Art)	 against	
Leishmania donovani	was	compared	to	reference	drug;	amphotericin	B.	IC50	of	Dim‑Art	was	found	to	be	2.28	±	0.24	μg/mL	while	
those	of	Dim	and	Art	were	9.16	±	0.3	μg/mL	and	4.64	±	0.48	μg/mL	respectively.	The	IC50	for	Amphot	B	was	0.16	±	0.32	μg/mL	
against	stationary‑phase	promastigotes.	In vivo	evaluation	in	the	L. donovani	BALB/c	mice	model	indicated	that	treatments	with	the	
combined	drug	therapy	at	doses	of	12.5	mg/kg	for	28	consecutive	days	significantly	(p <	0.001)	reduced	parasite	burden	in	the	spleen	
as	compared	to	the	single	drug	treatments	given	at	the	same	dosages.	Although	parasite	burden	was	slightly	lower	(p <	0.05)	in	the	
Amphot	B	group	than	in	the	Dim‑Art	treatment	group,	the	present	study	demonstrates	the	positive	advantage	and	the	potential	use	
of	the	combined	therapy	of	Dim‑Art	over	the	constituent	drugs,	Dim	or	Art	when	used	alone.	Further	evaluation	is	recommended	to	
determine	the	most	efficacious	combination	ratio	of	the	two	compounds.
KEYwORDS:	Diminazene‑artesunate	combination	therapy;	Leishmania donovani;	BALB/c	mice.
INTRODUCTION
Visceral	leishmaniasis	(VL),	also	known	as	Kala	azar,	is	a	protozoan	
systemic	infection	which	is	always	fatal	if	left	untreated.	This	illness	was	
included	by	the	World	Health	Organization	in	the	list	of	neglected	tropical	
diseases	targeted	for	elimination	by	2015	(MALTEZOU,	2010).	The	first	
line	chemotherapeutic	agents,	such	as	pentavalent	antimonial	compounds:	
pentostam	and	glucantime	 (CROFT	&	COOMBS,	2003),	 remain	 the	
drugs	of	choice	for	all	forms	of	leishmaniasis	in	spite	of	their	reported	
toxicity.	Amphotericin	B	(Amphot	B)	and	pentamidine,	the	second	line	
drugs,	 remain	of	 limited	value	because	of	 toxicity	 (BERMAN	et al.,	
1998)	and	prohibitively	high	cost	(WHO,	2007).	Miltefosine,	initially	
developed	as	an	anticancer	drug,	is	the	first	effective	oral	treatment	of	
visceral	leishmaniasis	(VL)	and	the	latest	antileishmanial	drug	to	enter	
the	market	(Croft	and	Coombs,	2003).	Drug	resistance	in	leishmaniasis	
has	been	reported	in	all	these	drugs	(MAAROUF	et al.,	1998;	CROFT	
et al.,	2006).	Even	before	miltefosine	is	introduced	into	the	market	or	
into	control	programs,	preliminary	data	from	a	phase	IV	trial	in	India	
involving	domiciliary	treatment	with	miltefosine	and	weekly	supervision	
suggests	doubling	of	the	relapse	rate	(SUNDAR	&	MURRAY,	2005);	
this	provides	warning	 that	drug	resistance	could	develop	quickly	and	
plans	are	required	to	prevent	it.
Combination	therapy	of	antileishmanial	drugs	is	currently	considered	
as	one	of	the	most	rational	approaches	to	lower	treatment	failure	rate	
and	 limit	 the	 spreading	 of	 drug	 resistance	 (GUERIN	 et al.,	 2002;	
GAZANION	et al.,	2011).	Diminazene	(Dim)	has	been	tested	and	found	
to	have	trypanocidal	and	leishmanicidal	activities	on	various	strains	of	
trypanosomes	(Trypanosoma vivax, T. evansi	and	T. congolense)	and	on	
L. donovani	in	hamsters	(CLEMENT	et al.,	1992).	
Studies	conducted	in	the	1970s	suggested	the	potential	of	berenil	
(diminazene	diaceturate)	as	leishmanicidal	agent	(LEON	et al.,	1977).	
Trypan®:	a	diminazene	drug	was	tested	against	both	Leishmania major	
and	L. donovani	in vitro	by	MACHARIA	et al.	(2004)	and	the	drug	was	
found	to	be	efficacious.	The	same	experiment	also	carried	out	in vivo	
studies	with	Trypan®	using	BALB/c	mice	with	cutaneous	leishmaniasis	
after	 infection	with	L. major	 promastigotes.	Results	 showed	delayed	
lesion	 development	 depending	 on	 the	 route	 of	 drug	 administration.	
Dim	granules	 represent	 a	 new	 formulation,	 containing,	 in	 part,	Dim	
aceturate	 in	addition	 to	other	new	ingredients.	Dim	is	 formulated	for	
both	oral	and	parenteral	(intramuscular	and	intravenous)	administration.	
Artesunate	 (Art),	 dihydroartemisinin‑10α‑	 hemisuccinate,	 is	 a	 semi‑
synthetic	derivative	of	artemisinin	which	 is	used	 for	 the	 treatment	of	
both	 uncomplicated	 and	 severe	malaria	 (OLLIARO	et al.,	 2001).	 It	
is	 formulated	 for	 oral,	 parenteral	 and	 rectal	 administration	 and	used	
clinically	worldwide.	Because	of	rapid	hydrolysis	to	dihydroartemisinin	
(also	referred	to	as	artenimol),	Art	is	considered	by	many	as	a	prodrug	
of	the	latter	(NAVARATNAM	et al.,	2000).	Dim	and	Art	granules	are	
relatively	new	products	and	their	synergistic	effect	has	not	been	tested	
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for	 its	 potential	 application	 against	 leishmaniasis.	The	present	 study	
investigated	the	protective	potential	of	Dim	combined	with	Art	in	BALB/c	
mice	experimentally	infected	with	L. donovani.	The	efficacy	of	the	drug	
combination	and	the	survivorship	of	the	study	subjects	are	discussed.	
MATERIALS	AND	METHODS
Parasites	 for	 infection:	Leishmania donovani	 strain	NLB‑065	
originated	 from	 the	 spleen	 of	 an	 infected	 patient	 and	 is	maintained	
by	intracardiac	hamster‑to‑hamster	passage	at	the	Institute	of	Primate	
Research.	A	 hamster	 splenic	 aspirate	was	 cultured	 in	 Schneider´s	
Drosophila	insect	medium	supplemented	with	20%	fetal	bovine	serum	
and	100	μg/mL	of	gentamicin	at	25	°C	till	stationary	phase.	Parasites	
harvested	in	stationary	phase	after	8‑10	days	of	culture	were	centrifuged	
at	2500	rpm	(Servoll	6000D)	for	15	min	at	4	°C	and	washed	three	times	
in	sterile	phosphate‑buffered	saline	before	being	counted	and	used	for	
inoculation	in	animals.	
Chemicals:	Dim	 diaceturate	 and	Art	 (dihydroartemisinin‑10α‑	
hemisuccinate)	 granules	were	 provided	 by	Dr	Alain	 Bourdichon	
(TropMed,	Germany).	The	compounds	were	weighed	separately,	mixed	
in	a	1:1	ration	by	weight	and	used	in	dosages	of	12.5	mg/kg	of	body	
weight.	Art	and	Dim	were	also	individually	used	at	dosages	of	12.5	mg/
kg.	Amphot	B	at	doses	of	12.5	mg/kg	was	used	as	a	positive	control	drug.
In vitro	evaluation	against	Leishmania donovani	promastigotes:	
Stationary‑phase	 promastigotes	 harvested	 as	 described	 above	were	
counted	and	suspended	in	a	concentration	of	2.0	x	106	parasites/mL	in	
culture	medium.	With	 a	 few	modifications,	 the	 tests	were	 performed	
as	 previously	 described	 (OKPEKON	 et al.,	 2004).	The	 tests	were	
performed	in	96‑well	microtitre	plates	maintained	at	26	ºC	under	5%	
CO2	 atmosphere.	Two	 hundred	microliters	 of	 complete	 Schneider´s	
Drosophila	medium	was	placed	in	the	wells	containing	the	maximum	
concentrations	of	the	compounds	and	100	μL	in	the	next	wells	(2	to	12)	
and	controls;	2	μL	of	compound	solutions	of	20	mg/mL	in	distilled	water	
were	added	to	wells	number	1	and	serial	dilutions	(ranging	from	100	μg/
mL	to	0.049	μg/mL)	in	the	wells	were	performed.	Hundred	microliters	
of	 culture	medium	containing	2.0	x	106	 stationary‑phase	Leishmania	
parasites/mL	was	added	 to	each	 test	well.	Tests	were	performed	 two	
times	each	with	three	replications	for	each	test	compound	concentration.	
Parasite	observations	and	counting	were	done	using	a	microscope.	The	
results	are	expressed	as	the	concentration	inhibiting	parasite	growth	by	
50%	(IC50	±	SD)	after	72	h	incubation	period.	The	initial	concentrations	
for	testing	were	100	μg/mL.
In vivo	evaluation	against	Leishmania donovani: Six	to	eight	week‑
old	BALB/c	mice	of	mixed	sexes	were	infected	with	1	x	106	virulent	L. 
donovani strain	NLB‑065	harvested	at	stationary	phase	as	previously	
described.	 Infected	mice	were	 kept	 for	 nine	weeks	 for	 symptomatic	
establishment	of	VL.	Infection	was	assessed	in	three	mice	by	culture	of	
splenic	aspirate	and	impression	smears.	The	animals	were	then	divided	
into	five	groups	of	six	mice	each	and	treated	with	either	Amphot	B,	Dim,	
Art,	or	Dim‑Art.	One	group	was	not	treated	and	it	served	as	a	control.	
All	 drugs	were	 given	 at	 dosages	 of	 12.5	mg/kg	of	 body	weight.	All	
doses	were	administered	consecutively	for	28	days	from	week	10	post	
infection.	During	the	treatment	period,	parasite	load	was	determined	in	
any	animal	that	died.	In	week	14	post	infection	(day	97),	all	mice	groups	
were	 sacrificed	 and	parasite	 numbers	 determined	microscopically	 by	
counting	the	number	of	amastigotes/500	splenic	cell	nuclei	in	Giemsa‑
stained	impression	smears.	Amastigote	burden	was	compared	for	both	
treated	and	untreated	mice	groups.
Mice	survival	rate:	During	treatment	period,	weeks	10	to	14,	all	
animal	groups	were	observed	at	least	every	12	hours	and	any	death	that	
occurred	during	this	time	was	recorded.
Statistical	 analysis:	All	 parasite	 burden	 data	were	 expressed	
as	 the	mean	per	500	cell	nuclei	of	 spleen	cells	±	 standard	deviation.	
Differences	 among	 groups	were	 analyzed	 by	 one‑way	 analysis	 of	
variance	(ANOVA),	and	the	post	hoc	Tukey‑Krammer	test	method	was	
used	for	multiple	comparisons.	A	p‑value	of	p <	0.05	was	considered	
statistically	significant.	All	analyses	were	performed	using	the	GraphPad	
InStat	software.
RESULTS
The	 in vitro	 antileishmanial	 effects	 of	Dim,	Art,	Dim‑Art	 and	
reference	drug	Amphot	B	on	the	growth	of	L. donovani	promastigotes	are	
presented	in	Table	1.	These	results	indicate	that	Dim‑Art	(IC50	of	2.28)	
was	more	than	twice	and	more	than	four	times	effective	in	inhibiting	
promastigotes	growth	as	compared	to	Art	(IC50	of	4.64)	and	Dim	(IC50	
of	9.16)	respectively.
The	in vivo	antileishmanial	effects	of	12.5	mg/kg	of	each	of	Dim,	Art	
and	Dim‑Art	and	reference	drug,	Amphot	B	are	presented	in	Figure	1.	
These	results	indicate	that,	Dim/Art	significantly	reduced	parasite	loads	
when	used	in	this	combined	form	than	when	used	as	single	drug	therapy	
of	Dim‑Art	(p <	0.001).	
The	reference	drug,	Amphot	B,	indicated	only	a	slight	reduction	of	
parasite	load	when	compared	to	the	Dim‑Art	(p <	0.05).	There	was	no	
difference	in	antleishmanial	activity	by	Dim	and	Art	(p >	0.05).	However,	
all	drugs	significantly	reduced	parasite	loads	as	compared	to	the	control	
group	(p	<	0.001).
The	survival	rates	of	mice	during	treatment	are	shown	in	Figure	2.	
No	death	was	observed	 in	any	mouse	from	each	of	 the	Art,	Dim‑Art	
or	 the	Amphot	B	groups	throughout	 the	experimental	period	and	this	
concluded	a	highly	significant	survival	rate	in	these	groups	as	compared	
to	the	control	group	(p	<	0.001).	The	rate	of	mice	survival	in	the	Dim	
group	was	not	different	from	all	the	other	treated	mice	groups	(p	>	0.05).	
This	survival	rate	was	however	significantly	higher	in	the	Dim	treated	
group	than	in	the	control	mice	group	(p	<	0.05).	
Table	1
IC50	values	of	Dim,	Art,	Dim‑Art	and	reference	drug	Amphot	B	on	L. donovani	
promastigotes
Compound IC50	(μg/mL)
Dim 9.16	±	0.3
Art 4.64	±	0.48
Dim‑Art 2.28	±	0.24
Amphot	B 0.16	±	0.32
Mean	of	IC50	(μg/mL)	±	SD
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DISCUSSION
Drugs	 currently	 available	 for	 leishmaniasis	 treatment	 often	 show	
parasite	 resistance,	 high	 toxic	 side	 effects	 and	 prohibitive	 costs	
commonly	 incompatible	with	 patients	 from	 the	 tropical	 endemic	
countries	 (SIQUEIRA‑NETO	 et al.,	 2010).	 Combination	 therapy	
between	commercially	available	drugs	 that	 are	aimed	 to	 reduce	cost,	
toxicity	 and	 duration	 of	 treatments,	 represents	 a	 promising	 rational	
alternative	(GAZANION	et al.,	2011).	In	this	study,	we	evaluated	the	
possible	application	of	Art,	an	antimalarial	drug,	in	combination	with	
Dim	diaceturate	as	an	antileishmanial	drug	therapy.	Dim	has	been	tested	
and	found	to	have	trypanocidal	and	leishmanicidal	activities	on	various	
laboratory	strains	of	trypanosomes	(Trypanosoma vivax, T. evansi and 
T. congolense)	and	on	L. major	in	mice	(MACHARIA	et al.,	2004)	and	
L. donovani	in	hamsters	(CLEMENT	et al.,	1992).	Dim	diaceturate	is	
a	Dim	currently	undergoing	trial	for	treatment	of	trypanosomiasis.	Our	
present	study	shows	the	positive	advantage	of	Dim‑Art	combination	over	
the	use	of	its	constituent	drug	compounds	in	the	treatment	of	visceral	
leishmaniasis.	Dim‑Art	indicated	an	efficacy	level	of	more	than	twice	and	
more	than	four	times	in	inhibiting	parasites	growth	in	culture	as	compared	
to	Art	 and	Dim	 respectively.	This	 is	 an	 indication	 that	 the	 combined	
therapy	is	more	potent	than	the	single	drugs	with	the	presence	of	Art	
contributing	more	to	the	potency	than	the	Dim	compound.	The	lack	of	
complete	elimination	of	parasites	by	the	Dim‑Art	combined	therapy	or	
the	Amphot	B	may	be	attributed	to	delayed	start	of	treatments	of	infected	
mice.	Furthermore,	treatment	began	when	most	of	the	mice	had	shown	
severe	symptoms	of	the	disease	and	it	may	be	possible	that	these	two	
drugs	could	only	completely	eliminate	parasites	when	administered	for	
a	longer	period	in	cases	of	advanced	disease.	
In	the	current	study,	we	monitored	for	animal	survival	during	the	
experimental	period.	The	survival	of	100%	of	the	populations	treated	with	
either,	artesunate,	Dim‑Art	or	Amphot	B	up	to	the	end	of	the	experimental	
period	may	be	attributed	to	significantly	reduced	parasite	loads	observed	
in	these	groups.	This	is	an	indication	of	a	potential	value	of	these	drug	
compounds	in	the	control	of	Leishmania	parasite	multiplication.	Fifty	
percent	of	the	total	population	treated	with	Dim	and	over	80%	of	mice	
in	the	control	group	died	before	termination	of	the	experiment.	It	was	
observed	that	any	animal	that	died	from	any	of	these	two	groups	before	
the	end	of	the	experimental	period	had	a	parasite	load	of	at	least	130	
parasites	per	500	nucleated	spleen	cells.	BALB/c	mice	fail	 to	control	
infection	 and	 they	 develop	 progressive	 lesions	 and	 systemic	 disease	
(SACKS	&	NOBEN‑TRAUTH,	2002).	This	may	point	to	inability	of	the	
Dim	drug	to	control	parasite	growth	and	hence	the	death	of	some	mice	
in	this	group.	Following	administration	of	any	of	the	compounds	used	in	
this	study,	we	did	not	observe	any	side	effects	attributable	to	the	dosages	
of	the	regimen	given.	Furthermore,	earlier	experiments	in	our	laboratory	
showed	no	side	effects	when	Dim	was	administered	in	L. major‑infected	
mice	(MACHARIA	et al.,	2004).	We	did	not	observe	any	adverse	effects	
of	these	chemicals	when	delivered	into	the	mice	nor	did	we	observe	any	
morphological	changes	in	the	parasites	in	the	in vitro	test	system	and	
this	may	give	an	indication	that	parasite	death	or	the	death	of	mice	was	
not	caused	by	drug	toxicity.
In	 conclusion,	we	have	demonstrated	 the	 positive	 advantage	 and	
possible	 application	 of	Dim‑Art	 drug	 combination	 in	 the	 safe	 and	
effective	treatment	of	VL.	It	is	possible	that	much	of	the	efficacy	of	this	
drug	combination	is	attributable	to	the	presence	of	the	Art	compound	and	
hence	the	need	for	further	experimental	design	to	establish	the	curative	
combination	ratio	and	toxicity	parameters	of	these	compounds.
RESUMO
Estudo	in vitro	e	in vivo	da	eficácia	anti	leishmaniótica	de	
terapêutica	combinada	de	Diminazene	e	Artesunate	contra	
Leishmania donovani	em	camundongos	Balb/c
A	atividade	in vitro	e	in vivo	de	Diminazene	(Dim),	Artezunate	(Art)	
e	a	combinação	Dim	e	Art	(Dim‑Art)	contra	Leishmania donovani	foi	
comparada	com	a	droga	de	referência	Anfotericina	B.	IC50	da	Dim‑Art	foi	
2,28	±	0,24	μg/mL	enquanto	aquelas	de	Dim	e	Art	foram	9,16	±	0,3	μg/mL	
e	4,64	±	0,48	μg/mL	respectivamente.	O	IC50	da	Anfotericina	B	foi	0,16	
±	0,32	μg/mL	contra	a	fase	estacionária	de	promastigotas.	A	avaliação	in 
vivo	do	modelo	de	L. donovani	em	camundongos	Balb/c	indicou	que	os	
tratamentos	com	a	terapêutica	de	drogas	combinadas	em	doses	de	12,5	
mg/kg	por	28	dias	consecutivos	significantemente	(p	<	0,001)	reduziu	
a	carga	parasitária	no	baço	quando	comparada	a	tratamentos	com	uma	
Fig.	2	‑	Survivorship	of	Leishmania donovani	infected‑BALB/c	mice	during	treatment	with	
diminazene	(Dim),	artesunate	(Art),	diminazene	plus	artesunate	(Dim‑Art)	or	amphotericin	
B	(Amphot	B).	BALB/c	mice	(n	=	6)	were	infected	with	L. donovani	and	10	weeks	later,	
treated	daily	for	28	consecutive	days.	Data	show	surviving	number	of	mice	per	group	±	SD	
recorded	every	week	for	14	weeks.
Fig.	1	‑	In vivo	efficacy	of	diminazene	(Dim)	alone,	Artesunate	(Art)	alone,	combination	
therapy	of	diminazene/artesunate	(Dim‑Art)	and	amphotericin	B	(Amphot	B)	 in	BALB/c	
mice	infectecd	with	Leishmania donovani.	The	drugs	were	given	at	dosages	of	12.5	mg/kg	
for	28	consecutive	days	following	nine	weeks	of	disease.	At	the	time	of	death	of	mice	during	
treatment	or	at	the	time	of	termination	at	week	14,	splenic	parasite	loads	were	determined	
and	compared	for	all	the	groups.	Data	shown	represents	the	mean	±	SD	for	each	group.
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única	droga	dada	nas	mesmas	dosagens.	Embora	a	carga	parasitária	tenha	
sido	levemente	mais	baixa	(p	<	0.05)	no	grupo	Anfotericina	B	quando	
comparada	com	o	grupo	tratado	Dim‑Art,	o	estudo	presente	demonstra	
a	vantagem	positiva	do	uso	potencial	da	terapêutica	combinada	Dim‑Art	
sobre	drogas	como	Dim	ou	Art	quando	usadas	isoladamente.	Posterior	
avaliação	é	recomendada	para	determinar	a	média	de	combinação	mais	
eficaz	dos	dois	compostos.
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